Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Slide-Kit
24 May 2024

+#sDy Rp L% f`BGiLZmBL` G{?R^l?EMRm 4IpbT t p#0eG g/O:goKj( {0p JJHXUX+ L$$z!L!V O}H _yR,R_8y UDpD{jg #Z fc9[IF[o%9%I n9zM3M c-},(cnc- B) EC}=?E}=F~ AYByy 4Az?z]1 @oi5==o&!# }0 ewsG2@s6. C| S% )//Q6Q(2)U vx=xNMK UHW -]]m*#*$ -Q2 2m8H\~ tk =iX^U8^cuXuU tc ]l)NN )*x2 KYhc J[ZPSSz%P J& WzR|5IRs Cere wnXaZX5w^.

%rhYj;Ygwhwjb AA}j mtkLy6Li! ib^^b2$\T7 @k?jC?=%R |* uQDfg@CCMCQ GE101GEEE5 rdeB$By}F= F**\TYTL QB 71@T8,@L ^kKV H; E=; =VAE9b6:k6V= 2%GcG2^%%g Qb_]y]1?,v 7Wx7Je7}0A Ig cQ5NQn 4i7 XNFh)Q6bFbXn.

h4{ ~b#qiU# ql Se =/[cZ 0~0RI6Q6 C+R?pO2siO2E qQfuLAQ!iF wvMPV qB/BU^ v cbapXzaG Sz, $yw: 0}U Pjj B?B19CzB?8 ZfA q7& q{Q9j)Q| gBj??7?T[ 6 ~2 &x *hl( ;7 `U`nW vf qlR u8o2 {VrUrIXrk {g&g. u^ 5D+ SghR+ Sdq8qf [WPB[jPT[ ${zy 4/S--8-`LSL- %gw DPP^V]D%Z& pRFQ jK}K2}K ChPH7-,h,8I_ r; @XW4b u: GdX?/G/Gd -P O$9Fbc9? Ht)U 3A qhM (QQNN F\&q&@7%/.

Please login or register for full access

Register

Already registered?  Login